Yaniv Sneor, co-founder of the Mid Atlantic Bio Angels (MABA), a life science angel investor group, joins Karen Rands on The Compassionate Capitalist Show to discuss the purpose and process of the investor network.
The life cycle and milestones used to measure progress and assess risk of Life Sciences companies as an early stage, pre-revenue company, are different than tech or consumer product companies. Often there isn't a tangible MVP (Minimum Viable Product), a prototype, or a beta to validate that the innovation works. Yet MABA seems to have broken the code and figured out how to evaluate, invest, and create a return on investment in the biomed, med tech, life sciences segment. Investors committed to bringing bio and medical innovations to the market are the minority in the broad scope of angel investors and angel investor groups. Learning from those investors that have figured out how to invest wisely and profiably in this complex sector is incredibly valuable.
Yaniv and Karen talk about:
- Key Milestones to consider that reduce inherent risk
- Importance of getting to exit without VC money
- How MABA offers Direct Investment and SideCar "Index" Fund
Yaniv has held every C-level position and led his companies through merger, acquisition, capitalization, and turnaround leadership with companies ranging from start-up to growth stage. Mr. Sneor is also currently the CEO of Native State Therapeutics, an early state biotechnology company in the neurodegeneration field.
Educated as an economist, Karen Rands is leading the Compassionate Capitalist Movement and author of the best selling Inside Secrets to Angel Investing. http:/InsideSecretstoAngelInvesting.com
Video version: https://youtu.be/hsKWwjuLsQY